Press Releases

Product Indications

VIVEVE®️ SYSTEM

In the United States the Viveve System is cleared by the FDA for general surgery procedures for electrocoagulation and hemostasis.

The Viveve System has received regulatory approvals and clearances in many countries throughout the world and is available through physician import license in Japan and China. International approvals and clearances include vaginal laxity and/or improvement of sexual function indications. In Argentina improvement of urinary incontinence in women is also an approved indication.

Nov 10, 2022 4:02pm EST

Viveve Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal PURSUIT Trial Readout

Sep 22, 2022 8:28am EDT

Press Releases

Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Viveve to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10, 2022

Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence

Viveve Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal PURSUIT Trial Readout

Viveve to Participate in Ladenburg Thalmann Healthcare Conference

Viveve to Participate in Alliance Global Partners Virtual MedTech Conference

Viveve to Participate in H.C. Wainwright 24th Annual Global Investment Conference

Viveve Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Viveve to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 11, 2022

Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan